AMENDMENT NUMBER ONE to the2019 Collaboration Agreement • February 28th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances)
This Amendment Number One (this “Amendment”), effective as of August 16, 2022 (the “Amendment Effective Date”), amends the 2019 Collaboration Agreement (the “Agreement”) dated August 16, 2019, by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Alector LLC, a Delaware limited liability company having an address at 131 Oyster Point Blvd., Suite 600, San Francisco, CA 94080 (hereinafter “Alector”). Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Agreement.
Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.2019 Collaboration Agreement • November 12th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances)
THIS 2019 COLLABORATION AGREEMENT (the “Agreement”) is made effective as of August 16, 2019 (the “Effective Date”), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ALECTOR LLC., a Delaware limited liability company having an address at 131 Oyster Point Blvd., Suite 600, San Francisco, CA 94080 and its Affiliates (“Alector”).
